We are pulmonary hypertension professionals united in our vision for a world without pulmonary vascular disease. We believe we can achieve this together, and we won’t stop until we do.
New IDDI leaders announced!
Meet the new faces guiding PVRI’s Innovative Drug Discovery Initiative - Gil Golden (UTC) and Sidra Hoffman (Gossamer Bio) join Sandeep Sahay and Luke Howard in the IDDI Leadership Team.
Whether you’re a pulmonary hypertension specialist, a pharmaceutical or industry colleague, a regulator, a patient, or a caregiver, joining our growing global family means you share our vision to reduce the global burden of pulmonary vascular disease.
Registrations & abstract submissions for PVRI 2026 will open on 1 July! Join us in the historic city of Dublin, 28 January – 1 February 2026, for cutting-edge science, global collaboration, and inspiring conversations. Stay tuned for full details on how to register and submit your abstract...
The Sixth Pulmonary Hypertension International Hybrid Meeting is going to be held from 10 - 11 July 2025 on behalf of Tuberculosis and Lung diseases Research Center of Tabriz University of Medical Sciences and Iranian society of Pulmonology. This meeting will be held with collaboration of Iranian society of Heart Failure.
Join an esteemed panel of international leaders as they share their approaches to bridging pediatric patients to lung transplantation. This dynamic session will feature focused presentations from each speaker, followed by interactive panel discussions of two real-world clinical cases.
Hypopituitarism has been reported in patients receiving continuous infusions of prostaglandin I2 (PGI2) analogues for pulmonary hypertension (PH). However, these patients' clinical characteristics, treatment, and prognoses remain unclear. This retrospective multicentre study included 22 patients who developed hypopituitarism while on continuous PGI2 analogue infusion between 1999 and 2021.
Pulmonary hypertension (PH) is a life-threatening condition frequently associated with exertional dyspnea. It remains diagnostically challenging due to limitations in current screening modalities. While the 6-min walk test (6MWT) has been applied for risk stratification in confirmed PH, its potential role in screening remains unexplored.
Children with chronic diseases, including pulmonary hypertension (PH), have an increased risk of anxiety and depression (AD), impacting mental health (MH), and quality of life (QoL). We sought to characterize the prevalence of AD in pediatric PH and identify associated factors. We developed a prospective cross-sectional study with 10 Pediatric Pulmonary Hypertension Network (PPHNet) centers.
We’re thrilled to announce a new chapter in the leadership of PVRI’s Innovative Drug Discovery Initiative (IDDI). We warmly welcome industry reps, Gil Golden (UTC) and Sidra Hoffman (Gossamer Bio), to the IDDI Leadership Team. They’ll be joining Sandeep Sahay and Luke Howard, who remain on as IDDI Leaders.
Your feedback is needed on our work groups and subject areas...We’re reviewing some of our IDDI Workstream activity, and we need you to help us shape the future agenda.
We’re pleased to share that the Pulmonary Hypertension Global Patient Survey (PHGPS) - a key project of the IDDI Patient Engagement & Empowerment (PE&E) Workstream - is now a stand-alone Task Force.
The PVRI 2025 Annual Congress was hosted in the vibrant city of Rio de Janeiro at the Windsor Convention & Expo Centre. Esteemed experts, healthcare professionals, and researchers from around the globe gathered in this iconic city to share groundbreaking insights, foster collaborations, and advance our collective mission towards conquering PVD.
